MILLENNIUM PHARMACEUTICALS, INC.
- Country
- πΊπΈUnited States
- Ownership
- Subsidiary
- Established
- 1993-01-01
- Employees
- 1K
- Market Cap
- -
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Single and Multiple Oral Dose of TAK-418 in Healthy Female Participants
- Conditions
- Interventions
- First Posted Date
- 2018-04-18
- Last Posted Date
- 2020-06-16
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT03501069
- Locations
- πΊπΈ
Parexel International, Glendale, California, United States
πΊπΈPRA Health Sciences, Salt Lake City, Utah, United States
A Study to Evaluate the Mass Balance, Pharmacokinetics (PK), Metabolism and Excretion of TAK-954 Containing Microtracer ([14C]-TAK-954) in Healthy Male Participants
- First Posted Date
- 2018-04-18
- Last Posted Date
- 2019-07-29
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT03500224
- Locations
- π³π±
PRAHS, Groningen, Netherlands
A Study to Evaluate the Effects of Rifampin on Pharmacokinetics (PK) of Pevonedistat in Participants With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2018-04-03
- Last Posted Date
- 2022-04-18
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT03486314
- Locations
- πΊπΈ
Greenville Health System - Institute for Translational Oncology Research, Greenville, South Carolina, United States
πΊπΈBarbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
πΊπΈEmory University, Atlanta, Georgia, United States
A Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of TAK-788 Followed by Evaluation of the Effects of a Low-Fat Meal on TAK-788 PK and Evaluation of Relative Bioavailability of TAK-788 Capsules in Healthy Participants
- First Posted Date
- 2018-03-29
- Last Posted Date
- 2020-01-29
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 69
- Registration Number
- NCT03482453
- Locations
- πΊπΈ
PRA Health Sciences, Salt Lake City, Utah, United States
TAK-954 in Critically Ill Participants With Enteral Feeding Intolerance (EFI)
- Conditions
- Interventions
- First Posted Date
- 2018-03-27
- Last Posted Date
- 2019-09-24
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 1
- Registration Number
- NCT03477903
- Locations
- π¨π¦
St. Paul's Hospital, Vancouver, British Columbia, Canada
π¬π§Cardiff and Vale University Health Board, Cardiff, Wales, United Kingdom
π¨π¦Royal Columbian Hospital, New Westminster, British Columbia, Canada
A Study of TAK-164 in Participants With Advanced Gastrointestinal (GI) Cancer Expressing Guanylyl Cyclase C (GCC)
- First Posted Date
- 2018-02-28
- Last Posted Date
- 2021-03-22
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 31
- Registration Number
- NCT03449030
- Locations
- πΊπΈ
SCRI - Tennessee Oncology Nashville - Southern Hills Clinic, Nashville, Tennessee, United States
πΊπΈMassachusetts General Hospital, Boston, Massachusetts, United States
πΊπΈUniversity of Colorado Cancer Center, Aurora, Colorado, United States
A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM)
- Conditions
- Interventions
- First Posted Date
- 2018-02-20
- Last Posted Date
- 2023-02-24
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT03439280
- Locations
- πΊπΈ
Washington University School of Medicine, Saint Louis, Missouri, United States
πΊπΈCity of Hope - Duarte, Duarte, California, United States
πΊπΈWeill Cornell Medical Center, Div. of Hematology Medical Oncology, New York, New York, United States
A Study to Evaluate the Effects of Pevonedistat on the Corrected QT (QTc) Interval in Participants With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2017-11-06
- Last Posted Date
- 2023-03-28
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 68
- Registration Number
- NCT03330106
- Locations
- πΊπΈ
University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
πΊπΈSarcoma Oncology Center, Santa Monica, California, United States
πΊπΈHenry Ford Hospital, Detroit, Michigan, United States
Efficacy and Safety of TAK-653 in Treatment-Resistant Depression
- First Posted Date
- 2017-10-18
- Last Posted Date
- 2018-02-22
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Registration Number
- NCT03312894
A Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) for TAK-906 in Participants With Diabetes Mellitus and Gastroparesis (DG) or With Idiopathic Gastroparesis (IG)
- Conditions
- Interventions
- First Posted Date
- 2017-08-31
- Last Posted Date
- 2021-01-06
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 51
- Registration Number
- NCT03268941
- Locations
- πΊπΈ
850 North Kolb Road, Tucson, Arizona, United States
πΊπΈ13055 Southwest 42nd Street, Miami, Florida, United States
πΊπΈ8200 Southwest 117th Avenue, Miami, Florida, United States